| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Jonathan Carmichael | |
| David Krantz | |||
| David Janik | |||
| Terrence Hallahan | |||
| P2860 | cites work | Early Administration of Low-Dose Aspirin for the Prevention of Preterm and Term Preeclampsia: A Systematic Review and Meta-Analysis | Q22306400 |
| A randomized trial of prenatal versus postnatal repair of myelomeningocele | Q24625226 | ||
| First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery | Q81575462 | ||
| First-trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses | Q81592117 | ||
| The efficacy of first-trimester PAPP-A and free beta hCG levels for predicting adverse pregnancy outcome | Q82741251 | ||
| Universal cervical-length screening to prevent preterm birth: a cost-effectiveness analysis | Q82885919 | ||
| Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting | Q83395075 | ||
| Efficiency of first-trimester growth restriction and low pregnancy-associated plasma protein-A in predicting small for gestational age at delivery | Q84061753 | ||
| First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A | Q84178412 | ||
| Committee Opinion No. 545: Noninvasive prenatal testing for fetal aneuploidy | Q85495453 | ||
| Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis | Q86011340 | ||
| Maternal serum placental growth factor and α-fetoprotein testing in first trimester screening for Down syndrome | Q86490608 | ||
| Potential diagnostic consequences of applying non-invasive prenatal testing: population-based study from a country with existing first-trimester screening | Q87011794 | ||
| Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate | Q28178563 | ||
| Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data | Q28211057 | ||
| Maternal morbidity associated with multiple repeat cesarean deliveries | Q28243198 | ||
| Cerclage for short cervix on ultrasonography in women with singleton gestations and previous preterm birth: a meta-analysis | Q28308051 | ||
| DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study | Q30414408 | ||
| Predictive values, relative risks, and overall benefits of high and low maternal serum alpha-fetoprotein screening in singleton pregnancies: new epidemiologic data | Q30805224 | ||
| Serum screening with Down's syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-analysis | Q33357689 | ||
| Obstetrical complications associated with abnormal maternal serum markers analytes | Q33387732 | ||
| Adverse pregnancy outcomes after abnormal first-trimester screening for aneuploidy | Q34002446 | ||
| DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study | Q34029044 | ||
| Use of folic acid for prevention of spina bifida and other neural tube defects--1983-1991. | Q34132508 | ||
| Screening, diagnosis, and management of intrauterine growth restriction | Q34133419 | ||
| Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study | Q34178184 | ||
| Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing | Q34256640 | ||
| Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. | Q34366368 | ||
| The length of the cervix and the risk of spontaneous premature delivery. National Institute of Child Health and Human Development Maternal Fetal Medicine Unit Network | Q34372307 | ||
| Progesterone and the risk of preterm birth among women with a short cervix | Q34658686 | ||
| Long-term medical and social consequences of preterm birth | Q34797403 | ||
| Predicting the risk of pre‐eclampsia between 11 and 13 weeks' gestation by combining maternal characteristics and serum analytes, PAPP‐A and free β‐hCG | Q35084932 | ||
| First-trimester prediction of preterm birth using ADAM12, PAPP-A, uterine artery Doppler, and maternal characteristics | Q36295872 | ||
| Chromosomal microarray versus karyotyping for prenatal diagnosis | Q36546668 | ||
| First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death | Q36585258 | ||
| Noninvasive detection of fetal subchromosome abnormalities via deep sequencing of maternal plasma | Q36595101 | ||
| Unexplained Elevations of Maternal Serum Alpha-Fetoprotein | Q36604740 | ||
| Maternal characteristics, mean arterial pressure and serum markers in early prediction of preeclampsia | Q36867367 | ||
| Planned vs emergent cesarean hysterectomy | Q36906310 | ||
| Multicenter randomized trial of cerclage for preterm birth prevention in high-risk women with shortened midtrimester cervical length. | Q37401903 | ||
| Effect of predelivery diagnosis in 99 consecutive cases of placenta accreta | Q37660858 | ||
| Prediction of adverse pregnancy outcomes by combinations of first and second trimester biochemistry markers used in the routine prenatal screening of Down syndrome | Q37741903 | ||
| Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. | Q37776132 | ||
| Screening for pre-eclampsia--lessons from aneuploidy screening | Q37831656 | ||
| Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: a systematic review | Q37901092 | ||
| Screening for abnormal placentation and adverse pregnancy outcomes with maternal serum biomarkers in the second trimester | Q38200952 | ||
| Fetal surgery for myelomeningocele and the incidence of shunt-dependent hydrocephalus | Q38498652 | ||
| Down syndrome screening in the first and/or second trimester: model predicted performance using meta-analysis parameters | Q39216527 | ||
| Optimizing the definition of intrauterine growth restriction: the multicenter prospective PORTO Study | Q39444826 | ||
| First- and second-trimester maternal serum markers for aneuploidy and adverse obstetric outcomes | Q39880571 | ||
| Preterm birth-associated cost of early intervention services: an analysis by gestational age. | Q40236958 | ||
| Placenta accreta is associated with elevated maternal serum alpha-fetoprotein | Q42066685 | ||
| Prospective detection of open spina bifida at 11-13 weeks by assessing intracranial translucency and posterior brain | Q42619456 | ||
| Prenatal serum alpha-fetoprotein screening for neural tube defects | Q42664740 | ||
| Elevated first trimester PAPP--a is associated with increased risk of placenta accreta | Q43738398 | ||
| Association between first-trimester maternal serum pregnancy-associated plasma protein-A and obstetric complications | Q43768827 | ||
| Combined screening for preeclampsia and small for gestational age at 11-13 weeks. | Q43823700 | ||
| Maternal cfDNA screening for Down syndrome--a cost sensitivity analysis | Q43872436 | ||
| Maternal morbidity in cases of placenta accreta managed by a multidisciplinary care team compared with standard obstetric care | Q44376426 | ||
| ACOG practice bulletin. Neural tube defects. Number 44, July 2003. (Replaces committee opinion number 252, March 2001). | Q44661393 | ||
| First-trimester Down syndrome screening using additional serum markers with and without nuchal translucency and cell-free DNA. | Q44729421 | ||
| First-trimester Down syndrome screening: free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. | Q45291831 | ||
| Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. | Q45295203 | ||
| First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency | Q45300866 | ||
| First-trimester maternal dried blood Down syndrome screening marker levels in early pregnancy loss | Q45302658 | ||
| Abnormal second-trimester serum analytes are more predictive of preterm preeclampsia. | Q46002205 | ||
| Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks | Q46321423 | ||
| Prediction of patient-specific risk for fetal loss using maternal characteristics and first- and second-trimester maternal serum Down syndrome markers | Q46389149 | ||
| Down syndrome biochemical markers and screening for preeclampsia at first and second trimester: correlation with the week of onset and the severity | Q46462668 | ||
| Quad screen as a predictor of adverse pregnancy outcome | Q46628047 | ||
| First-trimester or second-trimester screening, or both, for Down's syndrome | Q46799629 | ||
| Prediction of birth weight by fetal crown-rump length and maternal serum levels of pregnancy-associated plasma protein-A in the first trimester. | Q47255575 | ||
| Pregnancy-associated plasma protein A, free beta-hCG, nuchal translucency, and risk of pregnancy loss. | Q47260823 | ||
| Regionalization of care for obstetric hemorrhage and its effect on maternal mortality | Q47562504 | ||
| First-trimester placentation and the risk of antepartum stillbirth | Q47860545 | ||
| First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). | Q47860634 | ||
| Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth | Q47864591 | ||
| Second-trimester prenatal screening for Down syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse outcome | Q47866661 | ||
| Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. | Q51331330 | ||
| The clinical significance of low maternal serum alpha-fetoprotein. | Q52704007 | ||
| Assay precision of serum alpha fetoprotein in antenatal screening for neural tube defects and Down's syndrome. | Q53904391 | ||
| Sensitivity and specificity of ultrasound for the detection of neural tube and ventral wall defects in a high-risk population. | Q53924166 | ||
| Absence of nasal bone in fetuses with trisomy 21 at 11–14 weeks of gestation: an observational study | Q56764725 | ||
| Presence of fetal DNA in maternal plasma and serum | Q57075132 | ||
| Maternal serum analytes as predictors of IUGR with different degrees of placental vascular dysfunction | Q57212283 | ||
| UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation | Q57523616 | ||
| Presence of the ‘lemon’ sign in fetuses with spina bifida at the 10-14-week scan | Q57523645 | ||
| Ultrasound screening for anencephaly at 10-14 weeks of gestation | Q57523680 | ||
| Maternal Plasma Cell-Free Fetal and Maternal DNA at 11-13 Weeks' Gestation: Relation to Fetal and Maternal Characteristics and Pregnancy Outcomes | Q61847818 | ||
| Second-trimester maternal serum markers and placenta accreta | Q61859468 | ||
| Placenta accreta/percreta/increta: a cause of elevated maternal serum alpha-fetoprotein | Q67900177 | ||
| Adverse perinatal outcome in patients screen-positive for neural tube defects and fetal Down syndrome | Q71658492 | ||
| A randomized trial of prenatal ultrasonographic screening: impact on the detection, management, and outcome of anomalous fetuses. The RADIUS Study Group | Q72127815 | ||
| Estimating an individual's risk of having a fetus with open spina bifida and the value of repeat alpha-fetoprotein testing. Fourth report of the UK collaborative study on alpha-fetoprotein in relation to neural tube defects | Q72676557 | ||
| First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications | Q73070066 | ||
| Improvement in hindbrain herniation demonstrated by serial fetal magnetic resonance imaging following fetal surgery for myelomeningocele | Q73208171 | ||
| Elevated maternal serum alpha-fetoprotein with low unconjugated estriol and the risk for lethal perinatal outcome | Q74066821 | ||
| First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency | Q74223487 | ||
| Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome | Q74771276 | ||
| Risk factors for placenta accreta | Q77360650 | ||
| Cervical length at 23 weeks of gestation: prediction of spontaneous preterm delivery | Q77571808 | ||
| Low maternal serum PAPP-A and fetal viability | Q78140762 | ||
| A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A | Q78368763 | ||
| First-trimester screening for trisomies 21 and 18 | Q79133560 | ||
| Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler and PAPP-A at 11-14 weeks' gestation | Q79554986 | ||
| Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia | Q79829262 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 693-712 | |
| P577 | publication date | 2014-07-03 | |
| P1433 | published in | Journal of Clinical Medicine | Q27724774 |
| P1476 | title | Maternal Serum Screening Markers and Adverse Outcome: A New Perspective | |
| P478 | volume | 3 |
| Q50891866 | Pregnancy-Associated Plasma Protein A Levels in Late First Trimester Pregnancies with Small-for-Gestational Age Neonates: A Prospective Case-Control Study. | cites work | P2860 |
Search more.